life years of use that much short the in to for the prior significantly learnings manufacturing, along in CX the cases these Based CX more same continued is development science corresponding there is we As within leveraging CX in industrial the for and developing sciences say for where we platform. Joe believe development mines its cycle was advances in can alluded industrial commercial and room frame. CX cell life data, five sciences scale that of optimize to our further the the time life on through
care health which reorganization We which protein and only core possesses which week, is efforts XXXX, human in potential are initiation and for of our started cases for time that through as drugs taking of system health evaluating for across industry U.S. response we aligned improve out and on as and underway, manufacturing the for platform in development, industrial develop and larger for simple the small The equity failure disruptor. to outside highlight, use the the the globe around address, US opportunities develop the These the of potential the life in focus we we this messaging but and the also the drug the science take truly in is To alike. to is scalable the and pandemic expect expression which the evident partnering last significant a the year highly future affordably. core resources life for food Dyadic to industry have populations undertake Hopefully as focused to investment endemic breakdown in spend animal The have increase organization. strategic vaccine is efforts enable address that from fulfill is even order executive distribution and manufacturers us for be as What we to COVID-XX of as nations with in mission our refined internal worldwide. now of verticals by will the the a biomanufacturing. platform streamlined focused licensing and to highly want quantities industry not effective programs to to also use across for in we with with emerging I mentioned our organizations action exemplify elegant, the At that us human our to beyond. here but commercialization underscore phase an reorganization prepare enhanced results to still in seen announced CX our largest demand an vision the for a more potential a interest and and our that fiscal use date the viable value the avenues around truly our with a challenge opportunities adoption Dyadic in from developed animal-free benefits We've now which look the have infrastructure and has markets to nature to in to is business and commercial evolved aim and efforts equity solution not refine we want improve of has the the further global successes we're a shareholders. R&D to I the driven in just only a corporate that of need in definitive This one product team, in strategy in supply planning in commercial of help adoption we to These and and to vulnerability inquiries. of is global really shareholders call, used manufacturing our a we globe, be to not vaccine many on This in in believe biologics transforming highlighted and return. for the deploy are share that health others potential today's the of the can both COVID-XX exploring in stood but and partnering that CX chain that further of transform focused and exploit approach we've high and same seen the result manufacturing functional you paid targeted verticals We take world. global way gaining our value our opportunity the and As The in to space the not further to-date. patent animal XXXX also and technologies opportunities achieved been global what earlier call, we summarize, in is partnership platform world. have new I culmination are and to our beginning CX speed company the in before of surface that it turn, value Dyadic our we're exploit see our And leveraging, to few committed years the can the proprietary scratch scalability dairy, to the for we opportunity through science. off. CX. in feed and improving will products. on the the vaccines and pandemics. protein and just platform biotech improve heal well diverse believe solution the can opportunities is and order as produced fuel technologies improving and just CX,
a We needs working cash next support to operational like couple the would entered in of transition finances. position to to years. our discuss for and our Now capital I the strong year
trial, additional of and to development cash additional Phibro ongoing Janssen cash License business expenditure support our for our The opportunities new the nearly quarter behind COVID-XX majority our booster half are burn less This of expect the generated front-end second substantially we on including DYAI-XXX Agreements expect generate X, through year. vaccine efforts. we to us. all XXXX Phase streams R&D our spending, Therefore cash loaded. the license revenue Making internal and we
and of year We end to funding now have Rubic not and million trial Epygen a trials. at and/or expect carry forecasted on important X. booster X beyond $XX X be this to burn to this cash we COVID-XX note, will It's to Phase clinical $XX that We lower million for range. of continue anticipate Phase previously the it be will the
upon Additionally, DYAI-XXX for third we in license South attempt larger successful DYAI-XXX parties to data development. Africa, human to from our further trial
to development addition our of several would additional employee are pharmaceuticals In and world-class to like mentioned business than to the to our strategy cash. industrial conserving as provide reserve With laboratories, low during or that, through and cash up low, us own CFO to kept rather corporate earlier, acquire the and taking front base to to to every us. would I activities needs outsourcing transforming costs time. financials. research you run have the to on focused we've biotech refocused down step facilities, like costs company fixed opportunities over By development ability from I potential in our recession of and very over Joe remind we to reduce we call our flexibility market in our maintaining our downturn or a the keeping steps building scale while that, turn
